<DOC>
	<DOCNO>NCT00243347</DOCNO>
	<brief_summary>This study examine effect tumor AZD2171 , treatment NSCLC HNC . The safety tolerability AZD2171 also study .</brief_summary>
	<brief_title>The Effects AZD2171 Patients With Non-Small Cell Lung Cancer Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histologically cytologically confirm head neck cancer ( HNC ) unresectable stage IIIb IV nonsmall cell lung cancer ( NSCLC ) At least one lesion able used tumor biopsy measure FDGPET Scan Considered suitable treatment NSCLC prior biological immunological therapy disease Or consider suitable treatment metastatic recurrent HNC prior biological immunological therapy disease NSCLC : Have receive 2 previous chemotherapy regimens receive last chemotherapy radiotherapy within 28 day first dose AZD2171 HNC : Previous chemotherapy radiotherapy receive 28 day first dose AZD2171 Untreatable , unstable brain meningeal metastasis . Abnormal liver kidney blood chemistry History poorly control hypertension rest blood pressure &gt; 150/100 Recent ( &lt; 14 day ) major surgery surgical incision fully heal Diabetes patient type I insulin dependent diabetes poorly control type II Significant hemorrhage hemoptysis Presence necrotic/hemorrhagic tumor metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>RECENTIN</keyword>
</DOC>